YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model

Anti-Cancer Drugs

Volumn 22, Issue 5, 2011, Pages 454-462

  Nakahara, Takahito ^a   Yamanaka, Kentaro ^a   Hatakeyama, Shinji ^a   Kita, Aya ^a   Takeuchi, Masahiro ^a   Kinoyama, Isao ^a   Matsuhisa, Akira ^a   Nakano, Kenji ^a   Shishido, Takao ^a   Koutoku, Hiroshi ^a   Sasamata, Masao ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Apoptosis; docetaxel; survivin; taxane; YM155

Indexed keywords

1 (2 METHOXYETHOXY) 2 METHYL 3 (2 PYRAZINYLMETHYL)NAPHTHO[2,3 D]IMIDAZOLE 4,9 DIONE; ANTINEOPLASTIC AGENT; DOCETAXEL; SURVIVIN; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; MITOSIS INDEX; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; HUMANS; IMIDAZOLES; INHIBITOR OF APOPTOSIS PROTEINS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MITOSIS; NAPHTHOQUINONES; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79955063402     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328344ac68     Document Type: Article

References (36)

1. Tamm I,Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, et al. IAPfamilyprotein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998; 58:5315-5320. (Pubitemid 28551107)
2. Altieri DC. Survivin and IAP proteins in cell death mechanisms. Biochem J 2010; 430:199-205.
3. Ryan BM, O'Donovan N, Duffy MJ. Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 2009; 35:553-562.
4. Altieri DC. New wirings in the survivin networks. Oncogene 2008; 27:6276-6284.
5. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3:917-921. (Pubitemid 27353455)
6. Lu B, Mu Y, Cao C, Zeng F, Schneider S, Tan J, et al. Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res 2004; 64:2840-2845. (Pubitemid 38500623)
7. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003; 22:8581-8589. (Pubitemid 38019195)
8. Duffy MJ, O'Donovan N, Brennan DJ, Gallagher WM, Ryan BM. Survivin: a promising tumor biomarker. Cancer Lett 2007; 249:49-60. (Pubitemid 46442669)
9. Monzo M, Rosell R, Felip E, Astudillo J, Sánchez JJ, Maestre J, et al. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999; 17:2100-2104. (Pubitemid 29318841)
10. Zhang M, Coen JJ, Suzuki Y, Siedow MR, Niemierko A, Khor LY, et al. Survivin is a potential mediator of prostate cancer metastasis. Int J Radiat Oncol Biol Phys 2010; 78:1095-1103.
11. Kim YH, Kim SM, Kim YK, Hong SP, Kim MJ, Myoung H. Evaluation of survivin as a prognostic marker in oral squamous cell carcinoma. J Oral Pathol Med 2010; 39:368-375.
12. Nouraee N, Mowla SJ, Ozhand A, Parvin M, Ziaee SA, Hatefi N. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker. Urol J 2009; 6:101-108.
13. Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, et al. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 2002; 59:1406-1412.
14. Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A 2002; 99:4349-4354. (Pubitemid 34285988)
15. Zhou J, Bi C, Janakakumara JV, Liu SC, Chng WJ, Tay KG, et al. Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood 2009; 113:4052-4062.
16. Swana HS, Grossman D, Anthony JN,Weiss RM, Altieri DC. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 1999; 341:452-453. (Pubitemid 29362524)
17. Crispen PL, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED. Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer 2008; 113:450-460.
18. Ye CP, Qiu CZ, Huang ZX, Su QC, Zhuang W, Wu RL, et al. Relationship between survivin expression and recurrence, and prognosis in hepatocellular carcinoma. World J Gastroenterol 2007; 13:6264-6268.
19. Yamamoto T, Tanigawa N. The role of survivin as a new target of diagnosis and treatment in human cancer. Med Electron Microsc 2001; 34:207-212.
20. Giodini A, Kallio MJ, Wall NR, Gorbsky GJ, Tognin S, Marchisio PC, et al. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res 2002; 62:2462-2467. (Pubitemid 34462718)
21. Mesri M, Morales-Ruiz M, Ackermann EJ, Bennett CF, Pober JS, Sessa WC, et al. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol 2001; 158:1757-1765. (Pubitemid 32422940)
22. Xing H, Weng D, Chen G, Tao W, Zhu T, Yang X, et al. Activation of fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells. Cancer Lett 2008; 261:108-119. (Pubitemid 351192224)
23. Derin D, Soydinc HO, Guney N, Tas F, Camlica H, Duranyildiz D, et al. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer. Lung Cancer 2008; 59:240-245. (Pubitemid 351173407)
24. Fan J, Wang L, Jiang GN, He WX, Ding JA. The role of survivin on overall survival of non-small cell lung cancer, a meta-analysis of published literatures. Lung Cancer 2008; 61:91-96.
25. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396:580-584. (Pubitemid 28563719)
26. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997; 57:4285-4300. (Pubitemid 27413438)
27. O'Connor DS, Wall NR, Porter AC, Altieri DC. A p34(cdc2) survival checkpoint in cancer. Cancer Cell 2002; 2:43-54.
28. Mesri M, Wall NR, Li J, Kim RW, Altieri DC. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 2001; 108:981-990. (Pubitemid 32946072)
29. Li W,Wang X, Lei P, Ye Q, Zhu H, Zhang Y, et al. Antisense RNA of surviving gene inhibits the proliferation of leukemia cells and sensitizes leukemia cell line to taxol-induced apoptosis. J Huazhong Univ Sci Technolog Med Sci 2008; 28:1-5.
30. Hu H, Li GX, Wang L, Watts J, Combs GF Jr, Lu J. Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and downregulates antiapoptotic proteins Bcl-XL and survivin. Clin Cancer Res 2008; 14:1150-1158. (Pubitemid 351302563)
31. Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, Matsuhisa A, et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007; 67:8014-8021. (Pubitemid 47395135)
32. Iwasa T, Okamoto I, Takezawa K, Yamanaka K, Nakahara T, Kita A, et al. Marked anti-tumor activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. Br J Cancer 2010; 103:36-42.
33. Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, Kuta M, et al. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol 2009; 27:4481-4486.
34. Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, et al. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer xenograft models. Cancer Sci 2011; 102:614-621.
35. Seo SK, Jin HO, Lee HC,Woo SH, Kim ES, Yoo DH, et al. Combined effects of sulindac and suberoylanilide hydroxamic acid on apoptosis induction in human lung cancer cells. Mol Pharmacol 2008; 73:1005-1012.
36. Reiner T, De las Pozas A, Gomez LA, Perez-Stable C. Low dose combinations of 2-methoyestradiol and docetaxel block prostate cancer cells in mitosis and increase apoptosis. Cancer Lett 2009; 276:21-31.